Michael P. Link
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael P. Link has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Crystal Wang
Department of Pediatrics, Stanford University School of Medicine
1 shared publicationEmily E. Johnston
Department of Pediatrics, Stanford University School of Medicine, Stanford, California
1 shared publicationJay Balagtas
Department of Pediatrics, University of California Davis, Sacramento, California
1 shared publicationJinah Kim
Department of Pathology, Stanford University School of Medicine, Stanford, California
1 shared publicationJohn Frederick Tan
Department of Pediatrics, Stanford University School of Medicine
1 shared publicationJong Chung
Department of Pediatrics, University of California Davis, Sacramento, California
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 2009016
Complete remission with single agent lorlatinib in children with ALK+ anaplastic large cell lymphoma and central nervous system involvement: a case report
Therapies targeting cancer-specific mutations can result in remarkable clinical responses while reducing adverse effects. We describe the use of lorlatinib, a potent oral inhibitor of anaplastic lymphoma kinase (ALK) that crosses the blood brain barrier (BBB), in a case report of two patients with refractory and relapsed ALK+ anaplastic large cell lymphoma (ALK+ ALCL) with central nervous system (CNS) involvement. In both cases, treatment with single agent lorlatinib led to rapid and durable complete remission with tolerable side effects. Furthermore, we also describe a novel application of next generation sequencing to characterize circulating immune receptor DNA sequences associated with ALCL, and tracked the molecular response to therapy with subsequent blood specimens. These cases demonstrate that utilization of an effective targeted therapy against cancer-specific driver mutations that penetrates the BBB can lead to a significant clinical response, and presents clonal tracking for molecular response assessment as a potential approach for further study.
- 4 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 2009016
Open AccessComplete remission with single agent lorlatinib in children with ALK+ anaplastic large cell lymphoma and central nervous system involvement: a case report
Therapies targeting cancer-specific mutations can result in remarkable clinical responses while reducing adverse effects. We describe the use of lorlatinib, a potent oral inhibitor of anaplastic lymphoma kinase (ALK) that crosses the blood brain barrier (BBB), in a case report of two patients with refractory and relapsed ALK+ anaplastic large cell lymphoma (ALK+ ALCL) with central nervous system (CNS) involvement. In both cases, treatment with single agent lorlatinib led to rapid and durable complete remission with tolerable side effects. Furthermore, we also describe a novel application of next generation sequencing to characterize circulating immune receptor DNA sequences associated with ALCL, and tracked the molecular response to therapy with subsequent blood specimens. These cases demonstrate that utilization of an effective targeted therapy against cancer-specific driver mutations that penetrates the BBB can lead to a significant clinical response, and presents clonal tracking for molecular response assessment as a potential approach for further study.
- 6 July 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (11) , 2025-2028
Subcutaneous panniculitis‐like T‐cell lymphoma: Pediatric case series demonstrating heterogeneous presentation and option for watchful waiting
Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) and primary cutaneous gamma delta T‐cell lymphoma (PCGD‐TCL) were initially both classified as subcutaneous panniculitis‐like T‐cell lymphoma. In 2008, SPTCL with alpha‐beta T‐cell receptor subtype was separated from primary cutaneous gamma delta T‐cell lymphomas (PCGD‐TCL). We report four pediatric cases that demonstrate the heterogeneity of each disease and show that PCGD‐TCL in children can have an indolent course, whereas SPTCL can behave aggressively. Three patients had spontaneous, durable remissions without treatment, whereas the one patient with disease progression was treated successfully. Watchful waiting may thus be appropriate for initial management of children. Pediatr Blood Cancer
- 6 July 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (11) , 2025-2028
Subcutaneous panniculitis‐like T‐cell lymphoma: Pediatric case series demonstrating heterogeneous presentation and option for watchful waiting
Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) and primary cutaneous gamma delta T‐cell lymphoma (PCGD‐TCL) were initially both classified as subcutaneous panniculitis‐like T‐cell lymphoma. In 2008, SPTCL with alpha‐beta T‐cell receptor subtype was separated from primary cutaneous gamma delta T‐cell lymphomas (PCGD‐TCL). We report four pediatric cases that demonstrate the heterogeneity of each disease and show that PCGD‐TCL in children can have an indolent course, whereas SPTCL can behave aggressively. Three patients had spontaneous, durable remissions without treatment, whereas the one patient with disease progression was treated successfully. Watchful waiting may thus be appropriate for initial management of children. Pediatr Blood Cancer
- 1 March 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (7) , 825-832
Collaborating to Conquer Cancer: Lessons From Our Children
- 1 March 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (7) , 825-832
Collaborating to Conquer Cancer: Lessons From Our Children